• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Nasdaq halts trading of L&H shares

Article

Troubles continue for voice recognition technology provider Lernout & Hauspie (HNN 10/18/00). With the U.S. Securities and Exchange Commission and the Easdaq stock exchange both investigating accusations of questionable accounting practices

Troubles continue for voice recognition technology provider Lernout & Hauspie (HNN 10/18/00). With the U.S. Securities and Exchange Commission and the Easdaq stock exchange both investigating accusations of questionable accounting practices by L&H, Easdaq and Nasdaq have halted trading of the company's shares. Trading will not resume on either exchange until the firm has fully satisfied Nasdaq's request for additional information.

L&H, which is also facing a number of class action lawsuits, is in the process of restating its financial results from the past two and a half years. The beleaguered VR vendor is considering measures including staffing cuts and pulling back product lines to speed its return to profitability.


© 2000 Miller Freeman Inc.
11/29/00, Issue # 117, page 5.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.